A comparison of in silico prediction of genotoxicity and carcinogenicity of drugs, with the results obtained from curated data in published literature.
SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules.
Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.
Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their R&D goals
Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.
▸ Resources ▸ Predicting genotoxicity and carcinogenicity of drugs and chemicals using using OECD QSAR, DEREK Nexus® and TEST
A comparison of in silico prediction of genotoxicity and carcinogenicity of drugs, with the results obtained from curated data in published literature.
© 2023. Syngene International Limited
We use cookies to improve your experience on our site and show you information relevant to your requirements.
To find out more, read our Privacy Policy and Cookies Policy.